3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Classical hematology
1
Conditions
Lymphoma, Non-Hodgkin
2
Lymphoma
2
Waldenstrom Macroglobulinemia
1
Thrombocytopenia
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma, B-Cell
1
Lung Neoplasms
1
Hodgkin Disease
1
Hand-Foot Syndrome
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
115
Dexamethasone
70
fludarabine phosphate
57
Cytarabine
56
fludarabine
52
Rituximab
51
Peripheral Blood Stem Cell Transplantation
40
Etoposide
40
Gemcitabine
39
Lenalidomide
38
pembrolizumab
33
Radiotherapy
33
Busulfan
33
Filgrastim
32
Carboplatin
31
Methotrexate
30
Cyclosporine
29
Cisplatin
29
Bortezomib
29
Mycophenolic Acid
28
Melphalan
28
venetoclax
27
Paclitaxel
26
Whole-Body Irradiation
24
Antilymphocyte Serum
23
Temozolomide
22
Granulocyte Colony-Stimulating Factor
20
Calcium Dobesilate
20
Bevacizumab
20
Tacrolimus
19
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Recurrence
×
Pharmacokinetics
×
Clear all
NCT04861181
2025-05-22
NIRAPK
Hospices Civils de Lyon
Phase 4
Terminated
12 enrolled